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GOAL (*in light of increasing data*):
“…determining which information is most 
relevant to the nanoscale science and 
engineering community.”
Hazard assessment studies of 
nanomaterials are proliferating
Source: http://icon.rice.edu/report.cfm
• How can we efficiently identify high quality
studies to meet our research needs?
Studies measure and report a range of 
parameters and characteristics
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Data quality/ 
presentation
What characteristics or 
criteria define a 
study as “high quality”?
Can we develop a tool that 
allows us to efficiently 
identify studies that meet 
these criteria?
Project Objective:
Develop a tool that uses Multi-Criteria 
Decision Analysis (MCDA) to identify 
studies that meet defined characteristics
• MCDA provides a framework to assist decision 
makers in choosing the best alternative from a 
range of alternatives amidst conflicting and 
competing criteria. 
• Can identify:
• Single most preferred option (study) or group of options 
(studies)
• Rank options
• Distinguish acceptable from unacceptable possibilities 
?
What will the MCDA tool do?
• Identify the “best” study (or studies) 
based on study criteria identified as 
important by the “stakeholders” 
(researchers, policy makers, etc.)
• Integrated with the Nanomaterial-
Biological Interaction (NBI) data 
repository
Image from http://zumaimaging.net
Project Status
1. Initial phase―
• Seek stakeholder input
• Develop test version of Tool
• Establish feasibility of concept
2. If proof-of-concept established, 
proceed with development
• Refine
• Program beta version of tool
• Integrate with databases
Initial Phase:  Specific steps
1. Identify stakeholders and goals
2. Identify criteria that define a 
“quality” study 
3. Build a decision framework
4. Rate studies based on criteria
5. Weight relative importance of 
criteria
6. Integrate results into test version
Identify stakeholders and goals
Image from http://blogbusinessworld.blogspot.com
• Who will use the tool?
• How will they use the information?
• What are their decision criteria for 
defining a study as useful/ not useful; 
high quality/ low quality?
Identify criteria that define a 
“quality study”
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• Call to develop standardized characterization criteria 
for hazard identification of nanomaterials
• Which criteria are *most important*?
Establish relationships between 
decision criteria and alternatives
Select 
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Weight the relative importance of 
criteria
Which do I consider more important…?
• Size distribution well characterized …or… 
better characterized surface chemistry?
• Standardized protocols…or…More 
replicates?
• Repeated dosing…or…Relevant exposure 
pathway?
Weight the relative importance of 
criteria
Criteria Wt Subcriteria Wt
Particle well-characterized 45
Size-distribution well-characterized 45
Composition/ surface-coatings well-
characterized
40
Highly pure 10
Relevant exposure 25
Relevant species 25
Relevant exposure route 20
Repeated exposure 10
Data quality 30
Standard protocol 25
Use of controls 30
Descriptive statistics 20
Rate studies
• Mine databases of nanomaterial 
studies
Rate studies
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opticsplanet.com; Oberdorster et al., 2005; topnews.in
Assessments may be factual or subjective
Rate studies
Subcriteria Study 1 Study 2 Study 3 Study 4
Size-distribution well-
characterized
5 3 2 1
Composition/ surface-coatings 
well-characterized
5 1 1 3
Highly pure 4 3 5 3
Relevant species 4 5 2 5
Relevant exposure route 2 5 3 3
Repeated exposure 3 5 2 1
Standard protocol 4 3 1 3
Use of controls 1 5 2 4
Descriptive statistics 2 3 2 4
1 = worst, 5 = best
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Integrate results
Subcriteria Wt
Rating Score
S1 S2 S3 S4 S1 S2 S3 S4
Size-distribution well-
characterized
45 5 3 2 1 225 135 90 45
Composition/ surface-coatings 
well-characterized
40 5 1 1 3 200 40 40 120
Highly pure 10 4 3 5 3 40 30 50 30
Relevant species 25 4 5 2 5 100 125 50 125
Relevant exposure route 20 2 5 3 3 40 100 60 60
Repeated exposure 10 3 5 2 1 30 50 20 10
Standard protocol 25 4 3 1 3 100 75 25 75
Use of controls 30 1 5 2 4 30 150 60 120
Descriptive statistics 20 2 3 2 4 40 60 40 80
Totals 805 765 435 665
Moving forward…
• Determine stakeholder priorities and 
define key criteria
• Integrate data and develop test 
version of Tool
• Establish Proof-of-Concept
• Refine
• Develop
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